SCHEMBL4674466

SCHEMBL4674466

O=C(O)C(O)=CC(=O)c1cc(Cc2ccccn2)co1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.39
L3MBTL1 Q9Y468 4/20 0.38
ALDH1A1 P00352 4/20 0.37
PTPRA P18433 1/20 0.37
IDO1 P14902 1/20 0.36
KDM4E B2RXH2 4/20 0.36
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
SMN1; SMN2 Q16637 4/20 0.36
CYP1A2 P05177 3/20 0.36
CYP2D6 P10635 1/20 0.36
MAPT P10636 1/20 0.36
TSHR P16473 1/20 0.36
HPGD P15428 2/20 0.35
GPR52 Q9Y2T5 1/20 0.35
ALOX15 P16050 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
HTT P42858 1/20 0.35
GLA P06280 1/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4674461 1.00 POLB (0.39) POLBL3MBTL1ALDH1A1PTPRAIDO1
SCHEMBL4675016 0.83 IDH1 (0.38) GPR52PTGER4
SCHEMBL4675020 0.83 IDH1 (0.38) GPR52PTGER4
SCHEMBL4677006 0.80 POLB (0.34) POLBL3MBTL1ALDH1A1PTPRAIDO1
SCHEMBL4675272 0.79 CES1 (0.35) POLBL3MBTL1ALDH1A1PTPRAIDO1
SCHEMBL4671718 0.79 HDAC1 (0.37) POLBALDH1A1MAPTTSHRGPR52
SCHEMBL4671722 0.79 HDAC1 (0.37) POLBALDH1A1MAPTTSHRGPR52
SCHEMBL4673313 0.79 KDM4E (0.39) POLBL3MBTL1ALDH1A1PTPRAIDO1
SCHEMBL4673318 0.79 KDM4E (0.39) POLBL3MBTL1ALDH1A1PTPRAIDO1
SCHEMBL5899398 0.79 ALDH1A1 (0.44) POLBL3MBTL1ALDH1A1PTPRAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 POLB 58/4885L3MBTL1 1170/4885ALDH1A1 980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.